Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | 650,000 | reported | 02 Feb 2026 | tx 5+1,425,360−150,000 |
| Dova Pharmaceuticals, Inc. | 21,700 | reported | 14 Aug 2018 | tx 4+68,609−26,809 |
| PhaseBio Pharmaceuticals Inc | 3,750 | reported | 19 May 2023 | tx 7+75,909−3,750 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 02 Feb 2026 | GRANT_AWARD | Fulcrum Therapeutics, Inc. | 650,000 | 0.00 USD | deriv |
| 24 Jan 2025 | GRANT_AWARD | Fulcrum Therapeutics, Inc. | 582,000 | 0.00 USD | deriv |
| 03 Jul 2024 | EXERCISE | Fulcrum Therapeutics, Inc. | 150,000 | 3.27 USD | |
| 03 Jul 2024 | EXERCISE | Fulcrum Therapeutics, Inc. | 150,000 | 0.00 USD | deriv |
| 04 Mar 2024 | PURCHASE | Fulcrum Therapeutics, Inc. | 43,360 | 11.35 USD | first after silence |
| 19 May 2023 | EXERCISE | PhaseBio Pharmaceuticals Inc | 3,750 | — | |
| 19 May 2023 | EXERCISE | PhaseBio Pharmaceuticals Inc | 3,750 | 0.00 USD | deriv |
| 19 May 2022 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 3,750 | 0.00 USD | deriv |
| 19 May 2022 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 17,500 | 0.00 USD | deriv |
| 03 Jun 2021 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 14,000 | 0.00 USD | deriv |
| 03 Jun 2020 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 4,909 | 0.00 USD | deriv |
| 12 Feb 2020 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 32,000 | 0.00 USD | deriv |
| 14 Aug 2018 | PURCHASE | Dova Pharmaceuticals, Inc. | 21,700 | 22.83 USD | first after silence |
| 22 Dec 2017 | EXERCISE | Dova Pharmaceuticals, Inc. | 26,809 | 3.73 USD | |
| 22 Dec 2017 | EXERCISE | Dova Pharmaceuticals, Inc. | 26,809 | 0.00 USD | deriv |
| 05 Jul 2017 | PURCHASE | Dova Pharmaceuticals, Inc. | 20,100 | 17.00 USD |
2 purchases reported after at least 12 months of silence — most recent on 04 Mar 2024.